Nachrichten zur BioMarin Pharmaceutical Aktie

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

…

BioMarin Pharmaceutical: Kursziel erhöht

San Francisco (www.aktiencheck.de) - Rating-Update: Die Einschätzung von Mohit Bansal, Analyst von Wells Fargo Advisors, für die Aktie von BioMarin Pharmaceutical…

BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript

…

BioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call Presentation

…

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the…

GMAB: 3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy…

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

…

BioMarin Pharmaceutical Inc. 2023 Q4 - Results - Earnings Call Presentation

…

BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript

…

Pro Research: Wall Street examines BioMarin Pharmaceuticals prospects By Investing.com

Pro Research: Wall Street examines BioMarin Pharmaceuticals prospects…

Buy These 4 Low-Beta Stocks to Counter Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron…

BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

BioMarin Pharmaceutical officer disposes stake worth $1.31M under trading plan

…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

BioMarin Pharmaceutical says CEO Bienaimé to retire, Hardy to take up post

…

BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript

…

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.…

[Latest] Global Hemophilia B Gene Therapy Market Size/Share Worth USD 5,938.5 Billion by 2032 at a 34.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 352.400$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-08-07...…

Insiderhandel: EVP, Chief Legal Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 983.662$

Davis, George Eric - Vorstand - Tag der Transaktion: 2023-08-08...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 529.740$

Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-08-08...…

Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo....…

BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended…

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the…

Biomarin Pharmaceutical Inc. Q2 Profit Increases, beats estimates

WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced earnings for its second quarter that increased from the same period last…

BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program…

BioMarin Pharmaceutical Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Earnings Outlook For Biomarin Pharmaceutical

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET

SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and…

BioMarin upgraded at BMO after FDA nod for hemophilia A therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy

Following FDAs approval, BioMarins (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A....…

BioMarin Pharma Announces FDA Approval Of ROCTAVIAN Gene Therapy

WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced the FDA approved ROCTAVIAN gene therapy for the treatment of adults with…

FDA approves BioMarin’s gene therapy drug for hemophilia

BioMarin Pharmaceutical Inc. BMRN received Food and Drug Administration approval of its gene therapy Roctavian to treat hemophilia A, the…

BioMarin granted FDA nod for hemophilia A gene therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

New Gene Therapy Could Face Uphill Battle

The potential FDA approval of BioMarins gene therapy for hemophilia A would be a major win, but patient uptake could…

Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...…

dpa-AFX ProFeed